Drugs / ORG-129
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04933565 | Jun 2021 → Dec 2022 | — | Origo Biopharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORG-129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04933565 ↗ |
| Route | Oral | “ORG-129 oral capsules” NCT04933565 ↗ |